隨著越來越多新的內視鏡技術的進展，越來越多病患接受消化道內視鏡檢查或更進一步
接受介入性內視鏡治療。近年來國人心血管事件的增加，新型抗血小板藥物的問世，內視鏡
醫師需考慮這些接受抗血小板製劑的患者在治療過程中此類藥物的使用與否，以及出血或栓
塞的風險性。根據目前歐美的準則，大多數的內視鏡處置前並不需要停止使用aspirin，但是
並非所有的亞洲醫師同意這樣的建議。未來，如何在出血及栓塞衡量風險，制定相關準則，
是重要的課題。

Following the rapid development of the endoscopic procedure, more and more patients received endoscopic
examination, as well as interventional treatments. These years, the increasing cardiovascular events and the newly
developed antiplatelet drugs make the endoscopists have to take the use of these drugs, and the associated risk of
bleeding and thromboembolic event into consideration during the management. According to the current guidelines
in western countries, it is unnecessary to stop aspirin before receiving most endoscopic procedures. However, not
all of the endoscopists in Asia agree with it. In future, it is an important issue in evaluation of the benefit and risk of
the use of antiplatelet drugs during endoscopic intervention. (J Intern Med Taiwan 2012; 23: 422-430)